A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 461,822 shares of AADI stock, worth $1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
461,822
Previous 439,222 5.15%
Holding current value
$1 Million
Previous $641,000 48.36%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.32 - $2.06 $29,832 - $46,556
22,600 Added 5.15%
461,822 $951,000
Q2 2024

Aug 09, 2024

SELL
$1.46 - $2.31 $152,570 - $241,395
-104,500 Reduced 19.22%
439,222 $641,000
Q1 2024

May 13, 2024

BUY
$1.59 - $2.44 $230,550 - $353,800
145,000 Added 36.37%
543,722 $1.27 Million
Q4 2023

Feb 13, 2024

BUY
$1.97 - $5.41 $301,016 - $826,648
152,800 Added 62.13%
398,722 $805,000
Q3 2023

Nov 14, 2023

BUY
$4.84 - $7.13 $202,312 - $298,034
41,800 Added 20.48%
245,922 $1.19 Million
Q2 2023

Aug 11, 2023

SELL
$6.84 - $8.56 $831,757 - $1.04 Million
-121,602 Reduced 37.33%
204,122 $1.4 Million
Q1 2023

May 12, 2023

BUY
$6.85 - $13.0 $510,338 - $968,526
74,502 Added 29.66%
325,724 $2.36 Million
Q4 2022

Feb 13, 2023

BUY
$11.99 - $14.5 $87,527 - $105,850
7,300 Added 2.99%
251,222 $3.22 Million
Q3 2022

Nov 14, 2022

BUY
$12.03 - $14.22 $846,912 - $1 Million
70,400 Added 40.57%
243,922 $3.45 Million
Q2 2022

Aug 12, 2022

BUY
$11.57 - $17.92 $393,380 - $609,280
34,000 Added 24.37%
173,522 $2.14 Million
Q1 2022

May 13, 2022

BUY
$16.65 - $24.97 $183,149 - $274,670
11,000 Added 8.56%
139,522 $2.37 Million
Q4 2021

Feb 11, 2022

SELL
$19.32 - $29.02 $717,409 - $1.08 Million
-37,133 Reduced 22.42%
128,522 $3.1 Million
Q3 2021

Nov 12, 2021

BUY
$25.52 - $41.85 $4.23 Million - $6.93 Million
165,655 New
165,655 $4.87 Million

Others Institutions Holding AADI

About Aadi Bioscience, Inc.


  • Ticker AADI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 21,016,800
  • Market Cap $45.6M
  • Description
  • Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...
More about AADI
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.